Yousif Capital Management LLC Reduces Stock Position in Halozyme Therapeutics, Inc. $HALO

Yousif Capital Management LLC trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 20.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 32,047 shares of the biopharmaceutical company’s stock after selling 8,029 shares during the quarter. Yousif Capital Management LLC’s holdings in Halozyme Therapeutics were worth $2,350,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of HALO. EverSource Wealth Advisors LLC increased its holdings in Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 174 shares during the period. Brown Advisory Inc. lifted its stake in Halozyme Therapeutics by 0.6% during the 2nd quarter. Brown Advisory Inc. now owns 35,057 shares of the biopharmaceutical company’s stock valued at $1,824,000 after acquiring an additional 224 shares during the period. VELA Investment Management LLC boosted its holdings in shares of Halozyme Therapeutics by 2.0% in the 2nd quarter. VELA Investment Management LLC now owns 12,989 shares of the biopharmaceutical company’s stock valued at $676,000 after acquiring an additional 260 shares during the last quarter. State of New Jersey Common Pension Fund D increased its stake in shares of Halozyme Therapeutics by 0.9% in the second quarter. State of New Jersey Common Pension Fund D now owns 42,473 shares of the biopharmaceutical company’s stock worth $2,209,000 after acquiring an additional 384 shares during the period. Finally, Cetera Trust Company N.A raised its holdings in shares of Halozyme Therapeutics by 7.4% during the second quarter. Cetera Trust Company N.A now owns 6,200 shares of the biopharmaceutical company’s stock worth $323,000 after purchasing an additional 425 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Up 0.7%

Shares of NASDAQ:HALO opened at $68.87 on Friday. The business’s 50 day moving average price is $67.34 and its 200-day moving average price is $65.49. Halozyme Therapeutics, Inc. has a 1 year low of $47.50 and a 1 year high of $79.50. The firm has a market capitalization of $8.10 billion, a price-to-earnings ratio of 14.50, a price-to-earnings-growth ratio of 0.37 and a beta of 0.95. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, topping the consensus estimate of $1.63 by $0.09. The company had revenue of $354.26 million during the quarter, compared to analyst estimates of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The firm’s revenue was up 22.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.27 EPS. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on HALO. Leerink Partnrs raised shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 14th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Tuesday, November 4th. The Goldman Sachs Group restated a “sell” rating and issued a $56.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 6th. Finally, Citizens Jmp increased their price target on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a report on Tuesday, November 4th. Six equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $75.10.

Insider Buying and Selling

In other Halozyme Therapeutics news, COO Cortney Caudill sold 4,263 shares of the stock in a transaction that occurred on Saturday, November 1st. The stock was sold at an average price of $65.19, for a total transaction of $277,904.97. Following the completion of the transaction, the chief operating officer owned 12,737 shares of the company’s stock, valued at $830,325.03. This represents a 25.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total value of $1,507,000.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares in the company, valued at approximately $55,285,726.65. This trade represents a 2.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 85,661 shares of company stock worth $6,036,837 in the last 90 days. Insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.